Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders (Q34726491)

4 August 2017

Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders (English)

1 reference

4 August 2017

Kevin Whelan

1

1 reference

4 August 2017

17 May 2013

1 reference

Proceedings of the Nutrition Society

4 August 2017

1 reference

4 August 2017

72

1 reference

4 August 2017

3

1 reference

4 August 2017

288-298

1 reference

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

4 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

The aetiology and impact of malnutrition in paediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Decrease in frequency of liquid stool in enterally fed critically ill patients given the multispecies probiotic VSL#3: a pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Mechanisms, prevention, and management of diarrhea in enteral nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Fructo-oligosaccharides and fibre in enteral nutrition has a beneficial influence on microbiota and gastrointestinal quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Inulin as the soluble fiber in liquid enteral nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Faecal microbiota and short-chain fatty acids in patients receiving enteral nutrition with standard or fructo-oligosaccharides and fibre-enriched formulas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Effects of total enteral nutrition supplemented with a multi-fibre mix on faecal short-chain fatty acids and microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Enteral-tube-feeding diarrhoea: manipulating the colonic microbiota with probiotics and prebiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

The role of probiotics and prebiotics in the management of diarrhoea associated with enteral tube feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Reversal by short-chain fatty acids of colonic fluid secretion induced by enteral feeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Intestinal microbiota in functional bowel disorders: a Rome foundation report

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Effect of antimicrobial agents on the ecological balance of human microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Covert assessment of concurrent and construct validity of a chart to characterize fecal output and diarrhea in patients receiving enteral nutrition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Assessment of fecal output in patients receiving enteral tube feeding: validation of a novel chart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Definitions, attitudes, and management practices in relation to diarrhea during enteral nutrition: a survey of patients, nurses, and dietitians

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

What's New on Defining Diarrhea in Tube-Feeding Studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Quantification of fructans, galacto-oligosacharides and other short-chain carbohydrates in processed grains and cereals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Fructan content of commonly consumed wheat, rye and gluten-free breads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

On the presence of inulin and oligofructose as natural ingredients in the western diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial: Table 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Specificity of Polysaccharide Use in Intestinal Bacteroides Species Determines Diet-Induced Microbiota Alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Postprandial metabolic events and fruit-derived phenolics: a review of the science

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Modulation of human dendritic cell phenotype and function by probiotic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Low counts of Faecalibacterium prausnitzii in colitis microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Etiology of perianal Crohn's disease: role of genetic, microbiological, and immunological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

New IBD genetics: common pathways with other diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Predicting a human gut microbiota's response to diet in gnotobiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Linking long-term dietary patterns with gut microbial enterotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Composition, variability, and temporal stability of the intestinal microbiota of the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Enterotypes of the human gut microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

A human gut microbial gene catalogue established by metagenomic sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Diversity of the human intestinal microbial flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Gut microbiota in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

The effect of irritable bowel syndrome on health-related quality of life and health care expenditures

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

Prebiotic effects: metabolic and health benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Enteral feeding: the effect on faecal output, the faecal microflora and SCFA concentrations

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Modification of the gastrointestinal microbiota and its application to clinical nutrition

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Defining and reporting diarrhoea during enteral tube feeding: do health professionals agree?

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Controlled trial of oligofructose in the management of irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Response to faecal challenge in defunctioned colonic Crohn's disease: prediction of long-term course

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans.

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Fecal microbiota in patients receiving enteral feeding are highly variable and may be altered in those who develop diarrhea

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Presence of inulin and oligofructose in the diets of Americans

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans.

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Nutritional problems in inflammatory bowel disease: The patient perspective

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Validation of a food frequency questionnaire to measure intakes of inulin and oligofructose

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Appetite during consumption of enteral formula as a sole source of nutrition: the effect of supplementing pea-fibre and fructo-oligosaccharides

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Formula delivery in patients receiving enteral tube feeding on general hospital wards: the impact of nasogastric extubation and diarrhea

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice

1 reference

https://api.crossref.org/works/10.1017%2FS0029665113001262

7 January 2021

10.1017/S0029665113001262

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

23680358